HC Wainwright & Co. Reiterates Neutral on NovoCure, Maintains $22 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar reiterated a Neutral rating on NovoCure (NASDAQ:NVCR) and maintained a $22 price target. This reflects the firm's ongoing assessment of NovoCure's market position and future prospects.
March 12, 2024 | 2:23 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. reaffirmed a Neutral rating on NovoCure, with a $22 price target, indicating a stable outlook on the company's stock.
The reiteration of a Neutral rating and maintenance of a $22 price target by HC Wainwright & Co. suggests a stable but cautious outlook on NovoCure. This indicates that the analyst sees limited upside or downside potential in the short term, based on the current information available.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 90